IntraOp Medical Corporation Announces Their 10th Mobetron with FLASH-IQ Installation Worldwide
11 May 2023
Phase 2
SUNNYVALE, Calif.--(BUSINESS WIRE)--IntraOp Medical Corporation proudly announces that its IntraOp® Mobetron® with FLASH-IQ™ technology will soon be installed in its tenth institution worldwide, marking a significant milestone in the study of FLASH radiotherapy.
'With the power of ten of the top academic institutions in the world with us, we are now committed more than ever to bring FLASH radiotherapy as a clinical option to cancer patients worldwide.'
IntraOp Mobetron with FLASH-IQ is a novel radiotherapy platform capable of delivering an Ultra-High Dose Rate (UHDR) electron beam. It must be noted that the Ultra-High Dose Rate (UHDR) functionality for FLASH Radiotherapy is for investigational use only and is not cleared yet for sale by the US FDA.
We acknowledge and thank the following institutions for their trust in IntraOp Mobetron with FLASH-IQ:
Lausanne University Hospital and University of Lausanne (CHUV), Lausanne, Switzerland
The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas
The Ohio State University Comprehensive James Cancer Center – Arthur G. James Cancer HospitalCancer Hospital and Richard J. Solove Research Institute (OSUCCC), Columbus, Ohio
The Institut Jules Bordet, Brussels, Belgium
Le Centre hospitalier de l’Université de Montréal (CHUM), Montreal, Canada
Heidelberg University Hospital, Heidelberg, Germany
University of Wisconsin Carbone Cancer CenterCancer Center, Madison, Wisconsin
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Moffitt Cancer Center, Tampa, Florida
Stanford Cancer InstituteCancer Institute, Palo Alto, California (installation in progress)
“FLASH-IQ isn’t just an IntraOp technology, it is the amalgamation of four years of excruciating research done by our BIG 3, the teams at CHUV, MDACC and OSUCCC,” said Sanjay Arora, CEO at IntraOp. “With the power of ten of the top academic institutions in the world with us, we are now committed more than ever to bring FLASH radiotherapy as a clinical option to cancer patients worldwide.”
Several additional sites are applying for IDEs in the US, along with Canada, Belgium and Germany applying for similar exemptions in their countries. IntraOp supports these applications and looks forward to the continued growth and development in the study of FLASH radiotherapy.
IntraOp® provides the first and most advanced platform for delivering Ultra-High Dose Rate (UHDR) radiotherapy with electrons, making it the de-facto system for electron FLASH clinical trials worldwide. By pioneering new advancements in radiotherapy, IntraOp equips oncologists to deliver the future of precision therapy, today. IntraOp is a cancer care company based in Sunnyvale, California, dedicated to Accelerating the Cure. For more information, please visit www.intraop.com.
Product photography available upon request
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.